Summary: A comprehensive study offers reassuring evidence for expectant mothers: the use of nonsteroidal anti-inflammatory drugs (NSAIDs) during the first trimester is not associated with an increased risk of major birth defects.<\/p>\n
Researchers analyzed over 260,000 pregnancies, finding no significant link between common medications like ibuprofen, diclofenac, or naproxen and congenital malformations. This research fills a critical gap in prenatal care, providing data-driven guidance for managing pain and fever during early pregnancy.<\/p>\n
Key Facts<\/p>\n
No Increased Risk: Exposure to NSAIDs in the first trimester showed no association with major congenital malformations overall, with a matched adjusted relative risk of 0.99.System-Specific Safety: The study found no increased risk for defects in specific organ systems, including the cardiovascular, musculoskeletal, central nervous, gastrointestinal, or genitourinary systems.Individual Drug Safety: No specific association was found for the most commonly used NSAIDs: ibuprofen (5.1%), diclofenac (1.6%), and naproxen (1.2%).Dose-Response Findings: Analyses revealed no significant link between the cumulative dose of NSAID exposure and the likelihood of birth defects.<\/p>\n
Source: PLOS<\/p>\n
Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, taken during the first trimester of pregnancy are not associated with an increased risk of major birth defects, according to a new study published May 14th\u00a0in the open-access journal\u00a0PLOS Medicine\u00a0by Sharon Daniel of Ben-Gurion University of the Negev and Clalit Health Services, Beer-Sheva, Israel, and colleagues.<\/p>\n
Pain and fever are common in early pregnancy and the options to manage them have been limited. Studies have raised safety concerns regarding acetaminophen while data on the safety of NSAIDs\u2014which include widely used medications such as ibuprofen, diclofenac, and naproxen\u2014has remained inconclusive.<\/p>\n
The new study used data from the Southern Israeli Pregnancy Registry (SiPREG) to analyze 264,858 singleton pregnancies between 1998 and 2018, of which 20,202 (7.6%) were exposed to NSAIDs during the first trimester\u2014most commonly ibuprofen (5.1%), diclofenac (1.6%), and naproxen (1.2%).<\/p>\n
Major congenital malformations were identified from linked clinical, hospitalization, and termination records. The researchers adjusted risks for maternal and pregnancy characteristics including maternal age, ethnicity, diabetes, obesity, folic acid use, and the reason for NSAID use.<\/p>\n
NSAID exposure was not associated with major congenital malformations overall (8.2% vs. 7.0% in unexposed pregnancies; matched adjusted relative risk = 0.99), nor with malformations in specific organ systems including the cardiovascular, musculoskeletal, central nervous system, gastrointestinal, and genitourinary systems.<\/p>\n
No association was observed for any individual drug, and dose-response analyses found no significant link between cumulative NSAID exposure and birth defect risk.<\/p>\n
\u201cOur results provide reassuring evidence that NSAID use in early pregnancy is not associated with major birth defects,\u201d the authors say. \u201cThese findings can help both pregnant women and physicians make informed decisions about managing pain and fever in early pregnancy.\u201d<\/p>\n
Dr. Daniel adds, \u201cWe used data from SiPREG, a large pregnancy registry in southern Israel that tracks medication use and pregnancy outcomes, including birth defects identified not only at birth, but also in pregnancy terminations and during the first year of life.\u201d<\/p>\n
\u201cWe examined whether common pain relievers from the NSAID group, such as ibuprofen, are linked to birth defects. We found no increased risk overall or for specific types of birth defects.\u201d<\/p>\n
Dr. Ariel Hasidim notes, \u201cOne of the most interesting parts of this research was finding a careful way to deal with gaps in real-world data. One key issue was that some people may have used common medicines like ibuprofen without it being recorded, which could affect the results. We tackled this head-on by using a special analysis to see whether and how this missing information might have influenced our findings.\u201d<\/p>\n
Key Questions Answered:Q: Can I take Advil for a fever in my first trimester now?<\/p>\n
A: This study provides \u201creassuring evidence\u201d that taking common NSAIDs like ibuprofen (Advil) in early pregnancy does not increase the risk of major birth defects. However, you should always consult your physician before starting any medication while pregnant.<\/p>\n
Q: Why was this study necessary if these drugs are so common?<\/p>\n
A: Options for managing pain in early pregnancy have been limited; studies raised concerns about acetaminophen, while previous NSAID data remained inconclusive. This large-scale study provides the clarity needed for informed medical decisions.<\/p>\n
Q: How did the researchers ensure the data was accurate?<\/p>\n
A: They used a massive registry (SiPREG) that tracked outcomes not just at birth, but also in terminations and through the first year of life. They also used special \u201csensitivity analyses\u201d to account for medications that might have been taken but not recorded.<\/p>\n
Editorial Notes:This article was edited by a Neuroscience News editor.Journal paper reviewed in full.Additional context added by our staff.About this pharmacology and neurodevelopment research news<\/p>\n
Author:\u00a0Claire Turner<\/a>
Source:\u00a0PLOS<\/a>
Contact:\u00a0Claire Turner \u2013 PLOS
Image:\u00a0The image is credited to Neuroscience News<\/p>\n